Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
Vasopressin is a synthetic hormone replacement therapy administered intravenously as a solution. It is indicated for acute management of variceal bleeding and maintenance of blood pressure in critically ill patients. The drug works by binding to vasopressin receptors to cause vasoconstriction and hemostasis.
Product is at peak commercial maturity with moderate competitive pressure; commercial teams are likely focused on market penetration and defending share against 30% competitive intensity.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency
Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
Intranasal Vasopressin Treatment in Children With Autism
The Effect of Vasopressin on Glucose Regulation
Worked on VASOPRESSIN at Gland Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on vasopressin offers stability within a peak-stage, hospital-focused product with established market presence and no imminent LOE threat. Roles are concentrated in acute care commercial execution, medical education, and account management rather than innovation pipeline work.